
Rita Leporati
@ritalepp
Medical Oncologist | Research Fellow @UNIMORE_univ | trained @IstTumori | #lungcancer
ID: 484620881
06-02-2012 09:40:26
67 Tweet
550 Followers
537 Following

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇





Our IASLC Academy is meeting today again!!, very happy to help young oncologists at the begining of their career! Rami Manochakian MD, FASCO Cancer Education #LCSM NO. #LungCancer Fawzi Abu Rous, MD @esinghimd Kaushal Parikh Aakash Desai, MD, MPH, FASCO SOFIA VIDAURRE MENDES Ramila David D. W. Lee, MBBS, FRCR. Rita Leporati @DrSteveMartin


Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵


Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 lungcancer-milan.com Hosted by Giuseppe Lo Russo with a world-class faculty



Faculty and meentees of our IASLC academy that is meeting today at #WCLC24 with Christian Rolfo Rami Manochakian MD, FASCO Cancer Education @DrSteveMartin Eric K. Singhi, MD Triparna Sen (Sen-Lab) Marina Garassino LudaBazhenovaMD Jyoti D Patel Aakash Desai, MD, MPH, FASCO and many others! #lungcancer #lcsm SOFIA VIDAURRE MENDES


Session on targeted therapy chaired by Drs. Rita Leporati giuseppe viscardi Claudia Proto with Luis Paz-Ares discussing #EGFR: FLAURA2 vs MARIPOSA - longer PFS but cost of toxicity & infusions. Many prognostic factors, need predictive ones. Ivonescimab - is this the future of IO for EGFR?



Excited to share our study on ALK-rearranged NSCLC! We report 3 cases of LCNEC transformation post-ALK-TKI, marking the first reported rate of histologic transformation (4%). Oncologists, be aware of this resistance mechanism! Istituto Tumori Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…

